Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone011-41-61-324-1111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$51.90 billion
Profitability
Miscellaneous
Employees125,161
Next Earnings Date10/22/2019 (Confirmed)
OptionableOptionable
Novartis (NYSE:NVS) Frequently Asked Questions
What is Novartis' stock symbol?
Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."
How often does Novartis pay dividends? What is the dividend yield for Novartis?
Novartis declared an annual dividend on Thursday, January 31st. Stockholders of record on Tuesday, March 5th will be given a dividend of $2.8646 per share on Wednesday, March 13th. This represents a dividend yield of 3.27%. The ex-dividend date of this dividend is Monday, March 4th. This is an increase from Novartis's previous annual dividend of $2.33. View Novartis' Dividend History.
How were Novartis' earnings last quarter?
Novartis AG (NYSE:NVS) released its quarterly earnings data on Thursday, July, 18th. The company reported $1.34 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.20 by $0.14. The business earned $11.76 billion during the quarter, compared to the consensus estimate of $11.45 billion. Novartis had a return on equity of 18.55% and a net margin of 23.27%. Novartis's quarterly revenue was up 3.7% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.29 earnings per share. View Novartis' Earnings History.
When is Novartis' next earnings date?
What price target have analysts set for NVS?
12 equities research analysts have issued 1 year target prices for Novartis' stock. Their predictions range from $79.16 to $105.00. On average, they expect Novartis' stock price to reach $91.94 in the next year. This suggests a possible upside of 6.0% from the stock's current price. View Analyst Price Targets for Novartis.
What is the consensus analysts' recommendation for Novartis?
12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 4 sell ratings, 1 hold rating, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.
Has Novartis been receiving favorable news coverage?
Media stories about NVS stock have been trending extremely negative on Tuesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novartis earned a news sentiment score of -4.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Novartis.
Are investors shorting Novartis?
Novartis saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,110,000 shares, a decline of 13.1% from the August 30th total of 3,580,000 shares. Based on an average daily volume of 2,000,000 shares, the short-interest ratio is currently 1.6 days. Currently, 0.1% of the shares of the stock are sold short. View Novartis' Current Options Chain.
Who are some of Novartis' key competitors?
Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), Eli Lilly And Co (LLY), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).
What other stocks do shareholders of Novartis own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), Intel (INTC), Walt Disney (DIS), AbbVie (ABBV), NVIDIA (NVDA), Cisco Systems (CSCO), AT&T (T), Gilead Sciences (GILD) and Merck & Co., Inc. (MRK).
Who are Novartis' key executives?
Novartis' management team includes the folowing people:
- Dr. Vasant Narasimhan, Chief Exec. Officer (Age 43)
- Mr. Harry Kirsch, Chief Financial Officer (Age 54)
- Mr. Steffen Lang, Global Head of Technical Operations (Age 52)
- Ms. Shannon Thyme Klinger, Group Gen. Counsel (Age 48)
- Dr. Klaus Moosmayer, Chief Ethics, Risk & Compliance Officer (Age 51)
Who are Novartis' major shareholders?
Novartis' stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (0.11%), Bristol John W & Co. Inc. NY (0.03%), Country Trust Bank (0.01%), Gofen & Glossberg LLC IL (0.01%), Confluence Investment Management LLC (0.01%) and Scout Investments Inc. (0.01%).
Which major investors are selling Novartis stock?
NVS stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank, Manning & Napier Group LLC, Scout Investments Inc., Crossmark Global Holdings Inc., Country Trust Bank, Park National Corp OH, Stonebridge Capital Management Inc. and Measured Wealth Private Client Group LLC.
Which major investors are buying Novartis stock?
NVS stock was bought by a variety of institutional investors in the last quarter, including Ferguson Wellman Capital Management Inc., Confluence Investment Management LLC, Bristol John W & Co. Inc. NY, Fox Run Management L.L.C., Clarus Wealth Advisors, Pacer Advisors Inc., Grassi Investment Management and Reilly Financial Advisors LLC.
How do I buy shares of Novartis?
Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Novartis' stock price today?
One share of NVS stock can currently be purchased for approximately $86.70.
How big of a company is Novartis?
Novartis has a market capitalization of $198.70 billion and generates $51.90 billion in revenue each year. The company earns $12.61 billion in net income (profit) each year or $5.09 on an earnings per share basis. Novartis employs 125,161 workers across the globe.View Additional Information About Novartis.
What is Novartis' official website?
How can I contact Novartis?
Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 011-41-61-324-1111 or via email at [email protected]
MarketBeat Community Rating for Novartis (NYSE NVS)
MarketBeat's community ratings are surveys of what our community members think about Novartis and other stocks. Vote "Outperform" if you believe NVS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVS will underperform the S&P 500 over the long term. You may vote once every thirty days.
